Mardi 24

0

Mardi 24

14h – 16 h : Sessions de communications affichées (sessions 1 à 10)

Salle GEORGE DE LA TOUR

Session 1 : Pharmacovigilance
Abstracts

Modérateurs : ??? 1/ Systematic detection of adverse drug effects in the elderly – partial results from 1279 patients. Véronèse L, Marquet P, Nouaille Y, Charmes JP, Merle L. 10 2/Adverse drug reactions in the elderly : a prevalence study in french public hospitals. Pouyanne P, Imbs JL, Bégaud B, Decker N, Haramburu F, Welsch M and the French Pharmacovigilance Centres. 11 3/Digoxin overdosage in the elderly. An underestimation of the renal deterioration due to ageing. Marquet P, Bouthier F, Charmes JP, Merle L. 12 4/Incidence des effets indésirables médicamenteux et des erreurs avec ou sans conséquences cliniques en médecine interne. Piquet C, Mallaret M, Bontemps H, Barjhoux C, Fabre M, Sarrot-Reynaud F, Imbert B, Bessard G. 13 5/ Hypersudation induite par les beta-bloqueurs : étude préliminaire à propos de 106 cas. Schmutz JL, Houet-Courtalon C, Tréchot P, Granel F, Reichert-Pénétrat S, Aliot E, Barbaud A. 14 6/ Atteinte hépatique sous anti-inflammatoires non stéroïdiens : Méthodologie d’une étude cas-témoin. Lacroix I, Bagheri H, Lapeyre-Mestre M, Montastruc JL, Réseaux GREG et Médecins Généralistes de Midi-Pyrénés. 15 7/ Concordance of patient questionnaire, medical charts and plasma assays to verify benzodiazepine use. Pierfitte C, Moore N, Pehourq F, Fourrier A, Thicoïpe M, Aissou M, Begaud B. 16 8/ Underevaluation of renal function deterioration in the elderly and adverse drug effects occurrence. Charmes JP, Marquet P, Bouthier-Quintard F, Nouaille Y, Merle L. 17 9/ Serious psychiatric disorders in an elderly population. Analysis of the databank of the french pharmacovigilance system over 2 years. Ferracin C, Guy C, Beyens MN, Ratrema M, Ollagnier M. 18 10/ Reporting of adverse drug reactions : comparison of the data of a cohort study and of spontaneous reporting. Haramburu F, Miremont G, Barlet MH, Weber F, Soubrié C, Bégaud B. 19 11/ Drug-induced hiccup : a review of the french pharmacovigilance database. Bagheri H, Cismondo S, Montastruc JL. 20 12/ Incidence of drug induced hepatic injuries in a source population : methodology and organization of the study hemeni. Sgro C, Lemoine A, Hillon P, Allard C, Chanay H, Lenoir C, Guilleminet C, Escousse A. 21 13/ Hypoglycémies sévères chez le sujet agé – ozidia® / glipizide à libération prolongée.

Jeans A, Reynier JC, Wohlhuter C, Pariente-Khayat A, Pierron E, Castot A. 22

Session 2 : Pharmacovigilance

Abstracts

Modérateurs :

1/ Drug Fever induced by etamsylate : results of a french national survey. Bellemin B, Vial T, Gallant C, Salley B, Evreux JC. 23 2/ Rôle de la Pharmacovigilance dans l’actualisation des résumés des caractéristiques du produit. Auguste V, Sergent B, Castot A. 24 3/ Proceedings in case of safety concerns in Europe : example of ozidia® Auguste V, Pariente-Khayat A, Pierron E, Castot A. 25 4/ Les hypertensions artérielles médicamenteuses. A propos de cinq observations. Gras-Champel V, Sauvé L, Decocq G, Yves FX, Plaquet O, Andréjak M. 26 5/ Oedemes angioneurotiques associés à la prise de dihydropyridines. Sauvé L, Gras-Champel V, Decocq G, Masson H, Andréjak M. 27 6/ L’absence d’adaptation posologique du fosinopril chez l’insuffisant rénal est-elle justifiée ? Olivier P, Germain ML, Trenque T, Carette B, Millart H, Choisy H. 28 7/ Syndrome cérébelleux après administration d’hydroquinidine. Une première observation. Blain H, Schmall-Laurain MC, Jellimann JM, Jeandel C, Blain A, Tréchot P. 29 8/ Heparin-induced thrombocytopenia (HIT) revisited. Lillo-LeLouët A, Lasne D, Chamoun K, Massonet-Castel S, Aiach M, Kreft-Jais C. 30 9/ Heparin-induced thrombocytopenia : successful anticoagulation with the low-molecular-weight heparinoïd Org 10172 during hemodialysis. Lamriben L, Ory JP, Delacour JL. 31 10/ Propacetamol handling and occupational contact dermatitis. Remblier C, Breuil K, Vandel B. 32 11/ Dermatose bulleuse et cefaloject ® Perault MC, Saadi A, Meunier R, Roujeau JC, Piriou A, Vandel B. 33 12/ Aphtose géante récidivante induite par le nicorandil. Mourtada I, Le Hir-Garreau I, Ollivier I, Bekourian F, Chevrant-breton J. 34 13 / Il faut qu’une neutropénie soit centrale ou périphérique.

Jasson-Molinier M, G, Soubrié C. 35

Session 3 : Pharmacovigilance

Abstracts

Modérateurs : 1/ In utero exposure to subutex induces no or mild withdrawal syndromes in the newborn. Marquet P, Lavignasse P, Chevrel J, Lachâtre G, Merle L. 36 2/ Insuffisance rénale néo-natale après exposition in-utéro à l’acide niflumique (nifluril®). Varin R, Noblet C, Broux F, Gubler MC, Landthaler G, Ensel P, Fessard C, Thuillez C. 37 3/ Report of two cases of exposure to high-dose antiandrogen during pregnancy : A successful outcome. Flangakis-Barbe S, Peyrière H, Roch I, Navarre-Belhassen C, Hillaire-Buys D, Blayac JP. 38 4/ Pregnancy outcome after first trimester fluoroquinolone exposure. Santolaria N, Vial T, Bellemin B, Evreux JC. 39 5/ Topical retinoids exposure in pregnancy. Coopérative évaluation from january 1992 to april 1997 : 132 cases and 94 with known pregnancy outcome. Carlier P, Choulika S, Dally S. 40 6/ Drug prescription during pregnancy. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. 41 7/ Subutex et grossesse. Jernite M, Hadidallah F, Alt M, Alt R, Welsch M, Brettes JP, Messer J. 42 8/ Gravité d’une réaction anaphylactique ou anaphylactoïde chez les patients traités par ß(-) à propos de trois cas dont une femme enceinte. Bavoux F, Arnault I, Soufir L, Hazebroucq V, Germain ML, Thebert D, Dhainaut JF. 43 9/ Abdominal lipomatosis and protease inhibitor : causal link ? Kreft-Jais C, Attar A, Hernigou A, Weiss L. 44 10/ Carcinome hepatocellulaire après traitement par danazol au long cours. Plantet F, Hulin C, Bureau C, Raby P, Feugier P, Witz F, Witz B, Guerci A, Lederlin P. 45 11/ Onset of diabetes mellitus under interferon therapy : report of five cases and review of the litterature. Djezzar S, Poinsignon Y, Gautier JF, Mariette X, Grunenberger F, Estève E, Vignes S, Dally S. 46 12/ Ulcérations muqueuses topographiquement atypiques avec l’alendronate.

Spreux A, Ampelas M, Bolla G, Baldin B. 47

Session 4 : Pharmacologie cardiovasculaire : Contrôle central de la pression artérielle. Modèles d’animaux hypertendus, Vieillissement vasculaire.

Abstracts

Modérateurs : ??? 1/ Prolonged central muscarinic stimulation mediates soman-induced hypertension in freely moving rats. Létienne R, Bataillard A, Julien C, Barrès C, Lallement G, Sassard J. 48 2/ Physostigmine-induced pressor response in normotensive and spontaneously hypertensive rats. Lazartigues E, Tellioglu T, Brefel-Courbon C, Tran MA, Montastruc JL, Rascol O. 49 3/ Evidence for a decrease in central sympathetic activation induced by acetylcholine in obese-hypertensive dogs. Verwaerde P, Lazartigues E, Pelat M, Tran MA, Gharib C, Senard JM, Rascol O, Montastruc JL. 50 4/ Sustained antihypertensive effect of chronic treatment with rilmenidine in SH-rats. Monassier L, Roegel JC, Feldman J, Bousquet P. 51 5/ Effects of chronic administration of the ACE-NEP inhibitor S 21-402 on circadian blood pressure profile in SHR. Bouchart F, Mulder P, Richard V, Henry JP, Lucien A, Lerebours G, Thuillez C. 52 6/ Aldosterone and pressure-natriuresis in the Lyon genetically hypertensive (LH) rat. Florin M, Lo M, Sassard J. 53 7/ Heat stress-induced myocardial protection in the isolated heart of transgenic ((mREN-2)27) hypertensive rats. Joyeux M, Lagneux C, Bricca G, Demenge P, Ribuot C. 54 8/ Role of endothelial factors on 1-adrenoceptor contraction in tail artery from hypertensive rats. Tabernero A, Vila E. 55 9/ Age-related changes in adenosine vaodilatation and L-name vasoconstriction. Hillaire-Buys D, Laurent F, Chapal J, Linck N, Loubatières-Mariani MM, Petit P. 56 10/ Influence of ageing on endothelium-dependent contraction in SHR’s aorta. Matz R, Van Overloop B, Gaubert E, Gairard A. 57 11/ Composition of thoracic aorta in a rat model of elastocalcinosis. Kieffer P, Giummelly P, Maquart FX, Hubert S, Atkinson J. 58 12/ Aortic stiffness and left ventricular hypertrophy in rats.

Niederhoffer N, Atkinson J, Giummelly P, Lartaud-Idjouadienne I 59

Session 5 : Pharmacologie cardio-vasculaire
Abstracts

Modérateurs :??? 1/ Beta-blocker treatment in experimental heart failure in rats. Mansuy P, Mougenot N, Ramirez-Gil JF, Moreau-Raillecove F, Rousselot-Bonnefond D, Komajda M, Lechat P. 60 2/ Les anomalies métaboliques du muscle squelettique dans l’insuffisance cardiaque. Michel C, Chati Z, Escanye JM, Zannad F. 61 3/ Mechanisms involved in the endothelial dysfunction induced by chronic heart failure, and in the beneficial effects of physical exercise or agiotensin-converting enzyme inhibition. Varin R, Mulder P, Tampion F, Richard V, Devaux C, Henry JP, Thibault N, Lerebours G, Thuillez C. 62 4/ Lipoperoxidation and the beta-adrenergic signaling during hypoxia-reoxygenation in rabbits. Merial C, Boyer MJ, Montastruc JL, Rougé P. 63 5/ Effect on rat aortas of methyclothiazide and indapamide. Comparison with hydrochlorothiazide. Colas B, Masson H, Hary L, Slama M, Andréjak M. 64 6/ CCKa receptor activation induces vasopressin release and antidiuresis in monkeys. Roccon A, Marchionni D, Segondy D, Cazaubon C, Nisato D. 65 7/ Cardiovascular and aquaretic effects of vasopressin V2 receptor blockade in monkeys. Marchionni D, Roccon A, Segondy D, Cazaubon C, Nisato D. 66 8/ Nitric oxide and prostaglandins are involved in the renal vasodilatory effect of enalaprilat. Demeilliers B, Jover B. 67 9/ Differential effects of quinapril on tissular levels of angiotensin and bradykinin in rats. Lechat P, Mougenot N, Ghouadni A, Barthelemy C, Moreau-Raillecove F, Komajda M, Carayon A. 68 10/ Differences in the renin-angiotensin system between the two genetically normotensive strains of Lyon rats. Lantelme P, Lo M, Sassard J. 69 11/ The axiohome system as a tool for evaluating vascular remodeling : effect of streptozotocin-induced diabetes on the mesenteric vascular bed. Azay J, Mechaly I, Krosniak M, Cassanas G, Roque C, Justice D, Cahard D, Serrano JJ,Gros G. 70 12/ Impairement of adenosine-induced relaxation in thoracic aorta from streptozotocin-induced diabetic rats. Laurent F, Hillaire-Buys D, Portet K, Michel A. 71 13/ Enhanced selectivity of the orally active thrombin inhibitors S 18326 and S 31214, versus complement factor I, explains their lack of inflammatory side effects.

Rupin A, Vallez MO, Mennecier P, Courchay C, de Nanteuil G, Verbeuren TJ. 72

Session 6 : pharmacologie cardiovasculaire: Anti – hypertenseurs.

Abstracts

Modérateurs :??? 1/ Comparison of nifedipine immediate release and slow release on sympathetic activation in human hypertension. Bussy C, Boutouyrie P, Azizi M, Billaud E, Vincent A, Libersa C, Kolski H, Laurent S. 73 2/ Trough/Peak ratios of once daily beta-blockers an diuretics comply with FDA recommendations. Salvio C, Zannad F. 74 3/ The combination of 2 antihypertensive agents potentiate the magnitude and the duration of action of effects on blood pressure. Salvio C, Zannad F. 75 4/ More effective blood pressure control with felodipine-metoprolol combination than with amlodipine. 24 hour ambulatory blood pressure monitoring. Zannad F, Fluckiger L. 76 5/ Furosemide inhibits angiotensin II-induced contraction on human internal mammary artery and saphenous vein. Stanke F, Cracowski JL, Sessa C, Chavanon O, Bessard G, Devillier P. 77 6/ Modulation of angiotensin II-induced contraction by eicosanoids on human internal mammary artery. Stanke F, Devillier P, Chavanon O, Bessard G. 78 7/ Nitric oxide and shed membrane particles release during hypothermic cardiopulmonary bypass.

Brua C, Boidin P, Hugel B, Kleschyov A, Jirari A, Freyssinet JM, Eisenmann B, Beretz A. 79

Session 7 : Pharmacologie cardiovasculaire : Système sympathique, Neurokinines, adénosine.

Abstracts

Modérateurs :??? 1/ Simulated microgravity increases beta-adrenergic lipolysis in human adipose tissue. Barbe P 80 2/ Lipolytic effects of conventional ß3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells : Preliminary pharmacological evidence for a putative ß4-adrenoceptor. Galitzky J, Verwaerde P, Langin D, Montastruc JL, Lafontan M, Berlan M. 81 3/ A study of the cardiovascular actions of SR 58611 A, a beta3-adrenoceptor agonist in dogs central versus peripheral mechanisms. Montastruc JL, Verwaerde P, Pelat M, Galitzky J, Langin D, Lafontan M, Berlan M. 82 4/ Activation of antilipolytic a 2-adrenoceptors by adrenaline during exercisein human adipose tissue. Stich V, De Glisezinski I, Galitzky, Crampes F, Lafontan M, Hejnova J, Berlan M. 83 5/ Selective activation of ß3-adrenoceptors by octopamine in mammal fat cells. Carpéné C, Galitzky J, Atgié C, Fontana E, Lafontan M, Berlan M. 84 6/ Hyperadrénergie et hémodynamique après envenimation scorpionique expérimentale. Zeghal K, Hammami S, Sahnoun Z, Rebaï T. 85 7/ Subarachnoid hemorrhage induced sympathoexcitation is prevented by endothelin blockade. Gaudet-Lambert E, Lambert GW, Friberg P, Elghozi JL. 86 8/ Beta3-Adrenoceptor transduction pathway. Leblais V, Baro I, Le Marec H, Langin D, Balligand JL, Escande D, Gauthier C. 87 9/ Antidiarrheal effect of a non-peptide NK3 receptor antagonist, SR 142801, on Cl. Difficile and E. Coli toxins-induced diarrhea in guinea pigs. Theodorou V, Marche P, Corthier G, Emonds-Alt X, Fioramonti J, Bueno L. 88 10/ Differential effects of P2-receptor antagonists on adenosine-5′-O-(2-thiodiphosphate)-induced insulin secretion and vasodilatation. Chapal J, Hillaire-Buys D, Dietz S, Blayac JP, Loubatières-Mariani MM, Petit P. 89 11/ Study on the in vitro effects of specific phosphodiesterase inhibitors on human uterus motility.

Bardou M, Loustalot Bardou C, Taylor S, Naline E, Dumas M, Darbois Y, Frydman R, Advenier C. 90

Session 8 : Neuro-pharmacologie, Neurokinines, adénosine.

Abstracts

Modérateurs :??? 1/ Molecular and clinical evidence that dopaminergic receptors influence salivary secretion. Bagheri H, O’Connell D, Damase-Michel C, Lapeyre-Mestre M, Gourio F, Cismondo S, Senard JM, Rascol O, Montastruc JL. 91 2/ Dopaminergic inhibition of catecholamine secretion from adrenal medulla : Evidence that inhibition is mediated by DA2 but not DA1 dopamine receptors. Damase-Michel C, Montastruc JL, Tran MA. 92 3/ Study of mechanisms implicated in lactic acidosis-induced rat striatal dopamine release by in vivo microdialysis. Remblier C, Pontcharraud R, Piriou A, Huguet F. 93 4/ Measure of recovery of the dopamine neuronal transporter in rat striatum using an irreversible inhibitor.

Do Rego JC, Syringas M, Costentin J, Bonnet JJ. 94

Session 9 : Pharmacocinétique

Abstracts

Modérateurs :??? 1/ Differences in brain distribution of all-trans (ATRA) 13-CIS retinoic acid (13-CIS RA) and fenretinide (4 HPR) in rat. Le Doze F, Albessard F, Debruyne D, Moulin M, Defer G. 95 2/ Influence of molecular lipophilicity on the diffusion of arylpropionate non steroidal anti-inflammatory drugs (NSAIDs) into the cerebrospinal fluid. Matoga M, Péhourcq F, Lagrange F, Tramu G, Bannwarth B. 96 3/ Pharmacokinetic-Pharmacodynamic evaluation of penem antibiotics neurotoxicity assessed by E.E.G in rats. Dupuis A, Paquereau J, Debarre S, Couet W, Bouquet S. 97 4/ Pharmacokinetic-Pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats. Delon A, Huguet F, Brunet V, Courtois P, Bouquet S, Couet W. 98 5/ Pharmacokinetics of mycophenolate mofetil (MMF) in cystic fibrosis pulmonary transplanted patients. Billaud EM, Fombeur P, Guillemain R, Amrein C, Chevalier P, Guinvarch A, Antoine C, Glotz D. 99 6/ A pharmacokinetic-pharmacodynamic model of perindoprilat effects in severe congestive heart failure. Bellissant E, Giudicelli JF. 100 7/ In vivo stereoselective protein binding of etodolac : Effect of metabolites and endogenous compounds on interindividual variations. Mignot-Jarecki I, Gillet P, Bannwarth B, Benzoni D, Bertin P, Schaeverbeke F, Kuntz JL, Leloët X, Dehais J, Trèves R, Provost JC, de Chasteigner C, Magdalou J, Netter P, Lapicque F. 101 8/ Factors influencing high-dose-methotrexate (HD-MTX) pharmacokinetics in children : a population study. Le Guellec C, Odoul F, Lamagnère JP, Paintaud G, Saux MC, Autret-Leca E. 102 9/ Maternal and foetal concentrations of piperacillin : a population study. Paintaud G, Odoul F, Roth P, Le Guellec C, Bérard M, Malpesa A, Perrey C, Maillet R, Bechtel P, Autret-Leca E. 103 10/ Influence of non genetic factors on CYP2D6 activity. Vincent-Viry M, Fournier B, Galteau MM. 104 11/ Influence of stiripentol on carbamazepine-epoxidation in epileptic children. Calculation of in vivo inhibition constant Tran A, Rey E, Chiron C, Dulac O, Vincent J, Pons G. 105 12/ Carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Mohty M, Peyrière H, Guinet C, Hillaire-Buys D, Bode U, Navarro M, Blayac JP. 106 13/ Population pharmacokinetic of a low molecular weight heparin (nadroparin calcium) in infants and children after cardiac surgery.

Mismetti P, Laporte S, Piquet P, Doubine S, Touchot A, Decousus H. 107

Session 10 : Pharmacologie moléculaire et cellulaire, signalisation, transduction.
Abstracts

Modérateurs :??? 1/ Impact of G-proteins on calcium sensitivity of tension in the rat tail artery. Spitzbarth E, Petitcolin MA, Tschirhart EJ, Capdeville-Atkinson C. 108 2/ Effects of cinnarizine and flunarizine on mitochondrial permeability transition. Elimadi A, Bouillot L, Sapena R, Tillement JP, Morin D. 109 3/ Effects of bis (maltolato) oxovanadium (IV) (BMOV) treatment on insulin signaling pathways determined (in vivo) in skeletal muscle from normal or streptozotocin-induced diabetic rats. Poucheret P, Girn J, Chen X, J.H. McNeill JH. 110 4/ Activation of antiviral cytotoxic T lymphocytes by chimeric viral antigens : structural and functional studies. Hudrisier D, Mazarguil H, Gairin JE. 111 5/ Calcium is required for fMLP and PAF induced superoxide release from human umbilical cord blood-derived eosinophils. Zardini DM, Bueb JL, Tschirhart EJ. 112 6/ 5-HT1A autoreceptor control of serotoninergic neurons in knock-out mao A-/-mice. Evrard A, Seif I, Hamon M, Adrien J. 113 7/ Characterization of [35S]GTP S binding in D5-GH4C1 cells : evidence for GS and GZ activation by the D5 dopamine receptor. Grignon S, Sidhu A. 114 8/ Apparent inverse agonist properties of pirenzepine and methoctramine through muscarinic M2 receptors of pertussis toxin-sensitive G proteins. Daeffler L, Gies JP, Landry Y. 115 9/ Approches moléculaires du récepteur aux imidazolines. Greney H, Vonthron C, Heemskerk F, Pigini N, Brasili L, Bousquet P, Dontenwill M. 116 10/ Interleukin-2 inhibition of glucocorticoid-induced transcription in lymphoid cells : A posssible mechanism of protection against apoptotic cell death. Biola A, Pallardy M. 117 11/ Quantification of gene expression by competitive PCR – pitfalls and solutions.

Hoff H, Bricca G. 118